Lala R, Canavese F, Matarazzo P, Chiabotto P, De Sanctis C
Divisione di Endocrinologia Pediatrica, Ospedale Infantile Regina Margherita, Torino, Italia.
Pediatr Med Chir. 1991 Jan-Feb;13(1):73-5.
To evaluate the efficacy of early treatment of cryptorchidism, we studied 154 children, 133 with unilateral and 21 bilateral cryptorchidism, between the ages of 6 months and 6 years. Only fullterm newborns without other pathological signs were selected for treatment which was undertaken only after the sixth month of life, when the time of late spontaneous testicular descent has been passed. By clinical evaluation, cryptorchid testes were classified as not palpable, inguinal and prescrotal. Patients were treated by LHRH nasal spray 200 mcg in each nostril 3 times a day (total 1.2 mg/day) for 4 weeks. In the case of failure, HCG (500 I.U. im. 3 times a week for 3 weeks) was further administered. We considered as therapeutic success testicular descent into the lower half of the scrotum. By LHRH treatment 36 testes (20.5%) reached the scrotum, when HCG was added in unsuccessful cases 47 other gonads (26.8%) descended. Total descent rate by LHRH + HCG was 47.3% (table 1). Uni- and bilateral forms of cryptorchidism responded to therapy without any significant difference (table 2). Abdominal testes failed to descend into the scrotum, 28.7% of inguinal testes and 81.3% prescrotal testes descended. Scrotal descent was dependent only by position of cryptorchid testes and not by age of patients (table 3). Higher descent rates obtained at older ages were due to higher incidence of milder forms of cryptorchidism (table 3). Side effects of combined therapy were light. In our experience, medical treatment by LHRH + HCG started after the first 6 months of life causes testicular descent in about one half of testes; it can place into the scrotum gonads with better fertility prognosis.
为评估隐睾症早期治疗的疗效,我们研究了154名年龄在6个月至6岁之间的儿童,其中133名单侧隐睾症患儿,21名双侧隐睾症患儿。仅选择无其他病理体征的足月儿进行治疗,且仅在出生后第六个月后进行治疗,此时已过睾丸自发下降的晚期。通过临床评估,隐睾睾丸分为不可触及型、腹股沟型和阴囊前型。患者接受LHRH鼻喷雾剂治疗,每侧鼻孔200微克,每天3次(共1.2毫克/天),持续4周。若治疗失败,则进一步给予HCG(500国际单位,肌肉注射,每周3次,共3周)。我们将睾丸降至阴囊下半部视为治疗成功。通过LHRH治疗,36个睾丸(20.5%)降至阴囊,在治疗失败的病例中加用HCG后,另有47个性腺(26.8%)下降。LHRH + HCG的总下降率为47.3%(表1)。单侧和双侧隐睾症对治疗的反应无显著差异(表2)。腹腔内睾丸未能降至阴囊,28.7%的腹股沟型睾丸和81.3%的阴囊前型睾丸降至阴囊。阴囊下降仅取决于隐睾睾丸的位置,而非患者年龄(表3)。年龄较大时获得较高的下降率是由于较轻形式的隐睾症发病率较高(表3)。联合治疗的副作用较轻。根据我们的经验,出生后6个月后开始的LHRH + HCG药物治疗可使约一半的睾丸下降;它可将生育预后较好的性腺置于阴囊内。